Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Hua Medicine Reports Positive Data from US Trial of Novel Diabetes Treatment

publication date: Apr 27, 2020

Hua Medicine of Shanghai reported positive data from a US Phase I test of its type 2 diabetes treatment, dorzagliatin, both as a monotherapy and paired with a SGLT-2 inhibitor. The trial showed a synergistic effect in dual administration of dorzagliatin and empagliflozin, but no adverse PK results. Hua says dorzagliatin is a first-in-class, dual-acting glucokinase activator, designed to restore glucose homeostasis in T2D patients by the improving glucose sensor function. Hua expects dorzagliatin will become a first-line T2D therapy either as a mono- or combination treatment. More details....

Stock Symbol: (HK: 2552)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.